66762-68-3

Usage

Uses

Used in Food and Beverage Industry:
ETHYL 4-METHOXY-3-OXO-BUTANOATE is used as a flavoring agent for its fruity, sweet aroma, enhancing the taste and aroma of various food and beverage products.
Used in Perfume and Cosmetic Industry:
ETHYL 4-METHOXY-3-OXO-BUTANOATE is used as a fragrance ingredient in perfumes and cosmetics, providing a pleasant scent and contributing to the overall sensory experience of these products.
Used in Pharmaceutical Industry:
ETHYL 4-METHOXY-3-OXO-BUTANOATE is used as an intermediate in the synthesis of various drugs and medical compounds, playing a crucial role in the development of new pharmaceutical products.

Upstream product

• 13176-46-0 4-bromoethyl acetoacetate 
• 124-41-4 sodium methylate 
• 64-17-5 ethanol 
• 41051-15-4 4-methoxyacetoacetic acid methylester 
• 2033-24-1 cycl-isopropylidene malonate 
• 625-45-6 2-methoxyacetic acid 
• 638-07-3 ethyl (2-chloroaceto)acetate 
• 105-36-2 ethyl bromoacetate 
• 38870-89-2 Methoxyacetyl chloride 
• 67-56-1 methanol 

Downstream Products

• 175205-07-9 6-methoxymethyl-2-thiouracil 
• 67230-31-3 C₁₇H₂₄N₂O₆ 
• 3122-75-6 6-methoxymethyl-2-methyl-4(3H)pyrimidinone 
• 79534-96-6 γ-methoxy-β-aminocrotonic acid ethyl ester 
• 35339-97-0 Methyl-5-methyl-2-methoxy-methyl-3-furoat 
• 339278-89-6 6-methoxymethyl-2-phenylpyrimidin-4-ol 
• 325685-59-4 4-chloro-6-methoxymethyl-2-phenylpyrimidine 

Relevant academic research and scientific papers

5-[3-[PIPERIDIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS

The present invention discloses 5-[3-[piperazin-l-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives according to Formula (I), wherein R1, R2, R3a, R3b, R6a, R6b, the subscript n and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS 4 and 5 for the prophylaxis or treatment of inflammatory diseases or diseases involving degradation of cartilage or disruption of cartilage homeostasis, such as e.g. osteoarthritis.

Synthesis of diverse acyclic precursors to pyrroles for studies of prebiotic routes to tetrapyrrole macrocycles

A chemical model for the origin of tetrapyrrole macrocycles under prebiotic conditions entails the condensation of acyclic dicarbonyl compounds and α-aminoketones to form pyrroles that are equipped for subsequent self-condensation. Development and exploration of the scope of the chemical model (including combinatorial reactions, studies of the effects of structurally defective substrates, and reactions in aqueous or organic media) have relied on the availability of diverse starting materials prepared by traditional chemical synthesis methods. Here the synthesis of all acyclic dicarbonyl compounds and α-aminoketones used in the prior prebiotic model studies is described. There are five sets of acyclic dicarbonyl compounds including (i) β-ketoesters bearing diverse 4-substituents, (ii) levulinic acid derivatives bearing selected 5-substituents (i.e., analogues of δ-aminolevulinic acid, ALA), (iii) meso-substituted β-ketoesters, (iv) meso-substituted β-diketones that contain one 4-substituent, and (v) hybrid molecules that contain both the β-ketoacyl unit and the levulinic acid skeleton (or homologue thereof). A variety of α-aminoketones (homologues of ALA) also have been prepared. Altogether, the synthesis of 53 compounds is described, encompassing 28 new compounds as well as 25 known compounds that have been more fully characterized or prepared via alternative routes. The ability to convert selected acyclic compounds directly via pyrroles to porphyrinogens in a single-flask process may also prove useful in mainstream syntheses of diverse tetrapyrroles regardless of possible prebiotic relevance.

Synthetic method of 4-methoxyethyl acetoacetate

The invention discloses a synthetic method of 4-methoxyethyl acetoacetate. The method concretely comprises the following steps: 1, adding tetrahydrofuran to a reaction kettle, introducing an inert gas, setting the internal temperature to be 15-25DEG C, adding sodium hydride, controlling the system temperature to be 20DEG C, adding a methanol and 4-chloroethyl acetoacetate mixed liquor in a dropwise manner, reacting for 4-6h, heating the obtained system to 20-25DEG C, continuously reacting for 3-5h, and carrying out TLC detection until the reaction is finished; 2, cooling the above reaction system to -7-0DEG C, adding a hydrochloric acid solution to adjust the pH value of the reaction system to 11-13, and carrying out pumping filtration on the above obtained reaction solution to obtain a white solid; and 3, adding the obtained white solid to ethyl acetate, adding the hydrochloric acid solution in a dropwise manner at 0DEG C to gradually dissolve the solid and adjust the pH value of the reaction system to 2-4, carrying out pumping filtration on the obtained reaction solution, separating out an organic layer from the obtained filtrate, decolorizing the organic phase through a decolorizing agent, and steaming out the above solvent to obtain pure 4-methoxyethyl acetoacetate. The method has the advantages of implementation of the reaction at room temperature, obtaining of the above product after steaming at a low temperature, direct and effective reduction of the danger in the production process, and reduction of the content of impurities in the product.

IRE-1α INHIBITORS

PROBLEM TO BE SOLVED: To provide compounds which directly inhibit inositol requiring enzyme 1 (IRE-1α activity) in vitro, prodrugs, and pharmaceutically acceptable salts thereof. SOLUTION: The present invention provides a compound represented by formula (A) [R3 and R4 are H or the like; Q5-Q8, together with the benzene ring to which they are attached, form a benzofused ring, where at least one of Q5-Q8 is a heteroatom selected from N, O, and S. COPYRIGHT: (C)2016,JPOandINPIT

Discovery of novel dihydroimidazothiazole derivatives as p53-MDM2 protein-protein interaction inhibitors: Synthesis, biological evaluation and structure-activity relationships

Starting with Nutlins as an initial lead, we designed and generated bicyclic scaffolds aiming to place cis-bischlorophenyl moiety at the equivalent location where the hydrophobic interaction with MDM2 could be expected. As a result, we discovered novel MDM2 inhibitors possessing a dihydroimidazothiazole scaffold. Further exploration of the side chains on the dihydroimidazothiazole scaffold aided by molecular modeling resulted in compounds exhibiting almost comparable in vitro potency to Nutlin-3a.

DIPHENYLPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION THEREOF

The invention relates to 5,6-diphenylpyridine-3-carboxamide derivatives of general formula (I): where: R1 represents hydrogen or a (C1-C 4)alkyl; R2 represents: a monoazo saturated heterocycle of 5 to 7 atoms, the nitrogen atom being substituted with a (C1-C4)alkanoyl; NR10R11; a nonaromatic (C3-C10) carbocycle more than tri-substituted with (C1-C4)alkyl; a nonaromatic (C11-C12) carbocycle unsubstituted or mono-or polysubstituted with (C1-C4) alkyl; a monooxygenated saturated heterocycle with 5 to 7 atoms, more than tri-substituted with (C1-C4)alkyl; or R1 and R2, together with the nitrogen atom to which the above are bonded, form a 4-disubstituted piperidin- 1-yl group; the salts, solvates and hydrates thereof. The invention further relates to a method for production and therapeutic application thereof.